Chongkundang Holdings

KSC:001630 · KR7001630003

PharmaceuticalsSmall

360

Medium confidence — indicative

Value55

Profit price16

EV / EBIT18

Price / Owner Earnings13

Cash yield37

Owner Earnings Yield73

Dividend Yield1

Sales & asset price87

Price/Sales93

EV / Gross Profit73

Price/Book95

Quality64

Returns on capital77

Return on Capital78

Cash Return on Capital73

Return on Equity79

Profit margins67

EBIT Margin75

Gross Profitability59

Cash backing55

Cash Conversion77

Accruals19

Owner Earnings Margin70

Growth58

Sales growth13

Profit growth75

Profit Growth77

Long-Term EPS Growth64

Owner Earnings Growth84

Reinvestment57

Price momentum31

Safety27

Debt load29

Debt serviceability54

Refinancing92

Debt Payback15

Liquidity42

Sentiment52

Analyst ratings31

Expectations trend50

Market mood44

Value Creation10/20creating some value

Creates more value than its capital costs
Owner earnings growing
Owner earnings per share growing
Reinvests at strong returns
Solid earnings base

What this means

Chongkundang Holdings clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountrySouth Korea

IndustryPharmaceuticals

SizeSmall

TypePublic Company

ExchangeKOSE

Websiteckd-holdings.com

ISINKR7001630003

Last UpdateApr 2, 2026

Indices

KOSPI (South Korea)

Themes

Business IntelligenceConsulting

Description

Analysis

Middle-of-the-road

Chong Kun Dang Holdings Corp. is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.

The price is attractive. You pay 8.2× its owner earnings: the cash an owner could take out each year, which is in the historically attractive zone.

The trajectory is moderate and the balance sheet is stretched. The company scores 10/20 on our value-creation score: creating some value.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250

2026

All-time high

Mar 2026

All-time low

Jun 2026

Average rank

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023

Price/Sales

—

Price/Earnings

—

Price/Book

—

Dividend Yield

—

Value (overall)

—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Chongkundang Holdings with its peers

CKD Bio

KSC:063160

—

CountrySouth Korea

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Whanin Pharm

KSC:016580

CountrySouth Korea

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Kyongbo Pharmaceutical

KSC:214390

CountrySouth Korea

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Bora Pharmaceuticals

TAI:6472

CountryTaiwan

IndustryPharmaceuticals

SizeMedium

Full Stock Analysis →

Reyon Pharmaceutical

KSC:102460

CountrySouth Korea

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Boryung

KSC:003850

CountrySouth Korea

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View

1 · Watch OutGood· 100

Value

1 · ExpensiveGood Value· 100

Quality

1 · Weak FundamentalsHigh Quality· 100

Growth

1 · Tough TimesHigh Growth· 100

Safety

1 · High LeverageWell-Financed· 100

Sentiment

1 · SkepticismPositive· 100

Learn More →